M. Geraldes

发表

An adaptive randomized design with application to estimation

Connie Page, Vincent F. Melfi, C. Page, 2001 .

Comparative genotypic and antimicrobial susceptibility analysis of zoonotic Campylobacter species isolated from broilers in a nationwide survey, Portugal.

M. V. Cunha, A. Botelho, M. Geraldes, 2012, Journal of food protection.

APPRAISE 2. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome for the APPRAISE-2 Investigators*

Deepak L. Bhatt, D. Atar, P. Pais, 2011 .

Apixaban with antiplatelet therapy after acute coronary syndrome.

Deepak L. Bhatt, D. Atar, R. de Caterina, 2011, The New England journal of medicine.

Diagnosis of Tuberculosis in the Wild Boar (Sus scrofa): A Comparison of Methods Applicable to Hunter-Harvested Animals

M. Correia-Neves, M. Geraldes, V. Almeida, 2010, PloS one.

Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

D. Boulton, M. Pfister, M. Geraldes, 2009, Clinical pharmacology and therapeutics.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Clopidogrel in Atrial Fibrillation: Is There Any Justification Now in the Era of New Anticoagulants?

P. Kirchhof, S. Ernst, B. Prendergast, 2012 .

Apixaban versus warfarin in patients with atrial fibrillation.

D. Atar, Jun Zhu, P. Pais, 2011, The New England journal of medicine.

Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Efficacy and Safety of Ceritinib in Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Rearranged (ALK+) Non-Small Cell Lung Cancer (NSCLC): An Update of ASCEND-1

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

BM-32CERITINIB (LDK378) FOR TREATMENT OF PATIENTS WITH ALK-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES (BM) IN THE ASCEND-1 TRIAL

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

900 Efficacy and safety of apixaban compared to warfarin for prevention of stroke and systemic embolism in 18,201 patients with atrial fibrillation: Primary results of the ARISTOTLE Trial

C. Granger, L. Wallentin, R. Lopes, 2011 .

Diversity and composition of cultivable gut bacteria in an endemic island bird and its mainland sister species

E. Lobato, R. Covas, C. Doutrelant, 2017, Symbiosis.

Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.

Michael Thomas, A. Shaw, Gregory Riely, 2014 .

Antimicrobial susceptibility and oxymino-β-lactam resistance mechanisms in Salmonella enterica and Escherichia coli isolates from different animal sources.

E. Ferreira, V. Manageiro, M. Caniça, 2015, Research in microbiology.

Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trial

D. Atar, Jun Zhu, P. Pais, 2013 .

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

QT/QTc Prolongation in Placebo-Treated Subjects: a PhRMA Collaborative Data Analysis

P. Sager, M. Agin, G. Ferber, 2008, Journal of biopharmaceutical statistics.